|
27
|
Prospective, phase II
|
Severe neutropenia and infections
|
Donor mobilization: 7.5 μg/kg G-CSF; resolution of infection in 92.6 % of patients; 81.5 % OS on day +30; early administration after a median infection period of 6 days
|
[41]
|
|
49
|
Prospective
|
Neutropenia and invasive bacterial or fungal infection
|
Donor mobilization with 5 μg/kg G-CSF + 50 mg PDN. Mixed cohort, including 10 adults; 72 % OS on day +28 and 52 % OS on day +100
|
[42]
|
|
13
|
Prospective phase I/II
|
Neutropenia and severe infection
|
Donor mobilization with 5–10 μg/kg G-CSF; Collection through the bag method. 69 % OS on day +30
|
[90]
|
|
3
|
Prospective
|
CGD and invasive aspergillosis
|
Donor’s mobilization with 450 μg G-CSF + 8 mg DXM; one patient died for ARDS, one was lost at follow-up and died 1 year after discharge, one is alive
|
[49]
|
|
35
|
Retrospective
|
Febrile neutropenia or defective granulocyte function
|
Donor mobilization with 480 μg G-CSF + 8 mg DXM; OS 77.1 and 65.7 %, respectively, on day +30 and +60; 82.4 % infection-related OS
|
[40]
|
|
32
|
Retrospective
|
Sepsis and neutropenia
|
Donor mobilization with single-dose lenograstim + DXM 8 mg; 59 % OS (8/32 pts died for the underlying infection and 8/32 pts for non-infectious causes)
|
[39]
|
|
16
|
Retrospective
|
Severe neutropenia and documented bacterial and/or fungal infections in HSCT recipients
|
Donor mobilization with 8 mg DXM after 2007; unstimulated donors before 2007; 50 % OS on day +30
|
[37]
|
|
10
|
Retrospective
|
High risk febrile neutropenia with/without microbiologically documented severe infection
|
Donor mobilization with 5 μg/kg G-CSF + 8 mg DXM; Clinical response rate 62.9 %, 40 % infection-related mortality, 40 OS %
|
[91]
|
|
13
|
Retrospective
|
Febrile neutropenia
|
Resolution of the documented infection in 9/12 (75 %) pts; good early survival (12/14 courses of GTX, 86 %); poor long-term survival (5/13 pts, 39 %)
|
[47]
|
|
13
|
Retrospective
|
Severe infections and neutropenia
|
Donor mobilization with G-CSF 300 μg from day -3; complete or partial recovery in 6 and 3 of the 15 courses of GTX (40 and 20 % respectively)
|
[43]
|
|
13
|
Retrospective
|
Granulocyte dysfunction or severe neutropenia and acute life-threatening infections
|
Donor mobilization with 600 μg G-CSF + 8 mg DXM; complete or partial clinical response in 12/13 pts (92 %); 15 % infection-related mortality and 42 % OS
|
[38]
|
|
3
|
Retrospective
|
Secondary prophylaxis of invasive fungal infections during neutropenic episodes
|
Donor mobilization with G-CSF; concomitant combination antifungal therapy; no infection-related mortality
|
[39]
|
|
3
|
Prospective
|
Prophylaxis in HSC recipients with chronic infections
|
Donor mobilization with 480 μg G-CSF + 7.5 mg DXM; after transplant, no flares of the infections (active S. aureus liver abscesses, chronic pulmonary aspergillosis, soft tissue mucormycosis)
|
[50]
|
|
20
|
Prospective
|
Proven fungal or bacterial infection, unresponsive to anti-microbial therapy (n = 16). Poor control of fungal infection prior to allogeneic HSCT (n = 4)
|
In the curative group, infection was controlled in 11 out of 16 children. All patients treated pre-emptively survived the HSCT procedure
|
[24]
|
|
10
|
Prospective
|
CGD with severe infections
|
Resolution of infection in 9 out of 10 patients, despite the fact that 8 patients were alloimmunized and had poor recovery of transfused granulocytes
|
[65]
|
